NFKBIA
Reactivity: Human, Mouse, Rat
WB, ELISA, IHC (p), IF (cc), IF (p), FACS, IHC (fro)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Suitable for use in Western blot (1: 500-1: 1000) and Immunohistochemistry (1: 50-1: 100). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
1.0 mg/mL
Buffer
PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % Sodium Azide and 50 % Glycerol.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
-20 °C
Storage Comment
Store the antibody (in aliquots) at -20 °C.
Tsolou, Liousia, Kalamida, Pouliliou, Giatromanolaki, Koukourakis: "Inhibition of IKK-NFκB pathway sensitizes lung cancer cell lines to radiation." in: Cancer biology & medicine, Vol. 14, Issue 3, pp. 293-301, (2017) (PubMed).
Target
NFKBIA
(Nuclear Factor of kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, alpha (NFKBIA))
IKBA antibody, MAD-3 antibody, NFKBI antibody, AI462015 antibody, Nfkbi antibody, RL/IF-1 antibody, ECI-6/IKBA antibody, NFKBIA antibody, ikbaB antibody, wu:fb81f08 antibody, zgc:56666 antibody, zgc:77616 antibody, ikbaA antibody, wu:fj16a07 antibody, zgc:85769 antibody, NFKB inhibitor alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha b antibody, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha a antibody, NFKBIA antibody, Nfkbia antibody, nfkbiab antibody, nfkbiaa antibody
Background
Three major forms of IKB like molecules have been identified and each is characterised by multiple copies of ankyrin repeats. IkappaB alpha and IkappaB beta appear to be the major regulatory forms of IKB in most cells. These proteins interact with p65 or cRel containing forms of NFkappaB and block nuclear import by masking the nuclear localisation sequences of NFkappaB. The activation of NFkappaB involves the inducible phosphorylation and subsequent degradation of IkappaB. Immunoblotting easily detects the hyperphosphorylated forms of IkappaB alpha, but not phosphorylated IkappaB beta. Interestingly, IkappaB alpha and IkappaB beta mediate different NFkappaB responses. IkappaB alpha appears to control more transient activation of NFkappaB in response to an inducer, while IkappaB beta controls a persistent response. Bcl3 interacts with p50 and p52 containing forms of NFkappaB, but rather than being an inhibitor it appears to function to stimulate transcription. The degradation of IkappaB is confirmed by immunoblotting.Synonyms: I kappa B-alpha, I-kappa-B-alpha, IkB-alpha, IkappaBalpha, MAD3, Major histocompatibility complex enhancer-binding protein MAD3, NF-kappa-B inhibitor alpha, NFKBI